Combining GLP-1 drugs with Weight-Loss surgery: better results or just more pills?

NCT ID NCT06132477

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether people who take GLP-1 receptor agonists (like Ozempic or Wegovy) should continue them after having bariatric surgery. Researchers will compare weight loss, blood sugar control, gut health, and hunger in 150 adults who either keep taking the drug or stop before surgery. The goal is to see if combining both treatments leads to better outcomes than surgery alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GLP-1 receptor agonists (drugs like semaglutide or liraglutide)

What this could lead to

If it works, this could show that staying on GLP-1 drugs after bariatric surgery leads to greater weight loss and better blood sugar control, helping patients and doctors make informed treatment decisions.

What could go wrong

This is a single-center Phase 4 trial with 150 participants, so results may not apply to everyone. The study is still recruiting, and it's possible that continuing the drugs offers no extra benefit or causes more side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome diabetes mellitus hypertensive disorder metabolic syndrome X morbid obesity obesity disorder obstructive sleep apnea syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Missouri Hospital

    RECRUITING

    Columbia, Missouri, 65201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••